Literature DB >> 31039352

Multiple Coronary Artery Bypass Grafting for Kawasaki Disease-Associated Coronary Artery Disease.

Naoki Tadokoro1, Tomoyuki Fujita2, Satsuki Fukushima1, Yusuke Shimahara1, Yorihiko Matsumoto1, Kizuku Yamashita1, Naonori Kawamoto1, Etsuko Tsuda3, Soichiro Kitamura1, Junjiro Kobayashi1.   

Abstract

BACKGROUND: Although coronary artery bypass grafting (CABG) is the preferred choice for advanced Kawasaki disease (KD)-associated coronary artery disease, graft design such as number of grafts or type of conduits has not been fully established. We reviewed a series of patients who underwent single or multiple CABG for coronary artery disease of KD sequelae to investigate the optimum revascularization strategy.
METHODS: We enrolled a consecutive series of 102 CABG surgeries in 92 patients during the last 36 years. Mean patient age at CABG was 14.9 ± 10.4 years. Internal thoracic artery, radial artery, and gastroepiploic artery were used in 100 (98%), 18 (15%), and 4 (4%) cases, respectively. Patients were divided into 2 groups by single (n = 53) or multiple (n = 49) CABG.
RESULTS: Actuarial survival was 93% in single CABG and 91% in multiple CABG at 30 years (P = .71). There was no in-hospital mortality, but 6 deaths occurred long term, with no significant difference between the groups. Freedom from cardiac events was 45.2% in single CABG and 68.5% in multiple CABG at 25 years (P = .228), and reintervention to the left anterior descending (LAD) artery territory was the most common event. Graft patency of the internal thoracic artery-LAD artery graft was 81% in single CABG and 85% in multiple CABG at 25 years. Patency of the radial artery in the non-LAD artery territories was significantly greater than that of the saphenous vein graft at 10 years (91% vs 46%, P = .013).
CONCLUSIONS: Multiple CABG using arterial conduits is feasible, safe, and therapeutically effective long term for patients with advanced KD-associated coronary artery disease.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31039352     DOI: 10.1016/j.athoracsur.2019.03.079

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Evaluating the time-varying risk of hypertension, cardiac events, and mortality following Kawasaki disease diagnosis.

Authors:  Jennifer J Y Lee; Brian M Feldman; Brian W McCrindle; Ping Li; Rae Sm Yeung; Jessica Widdifield
Journal:  Pediatr Res       Date:  2022-08-24       Impact factor: 3.953

2.  Bilateral internal thoracic artery grafting in children under 5 years of age with Kawasaki disease: a case series.

Authors:  Yusuke Shimahara; Satsuki Fukushima; Naoki Tadokoro; Etsuko Tsuda; Takaya Hoashi; Soichiro Kitamura; Junjiro Kobayashi; Tomoyuki Fujita
Journal:  Eur Heart J Case Rep       Date:  2020-11-22

3.  Surgical myocardial revascularization outcomes in Kawasaki disease: systematic review and meta-analysis.

Authors:  Antonio Salsano; Jingda Liao; Ambra Miette; Massimo Capoccia; Giovanni Mariscalco; Francesco Santini; Antonio F Corno
Journal:  Open Med (Wars)       Date:  2021-03-09

4.  Myocardial infarction due to thrombotic occlusion despite anticoagulation in Kawasaki disease - a case report.

Authors:  Diana van Stijn; Nikki J Schoenmaker; R Nils Planken; Dave R Koolbergen; Samantha C Gouw; Taco W Kuijpers; Nico A Blom; Irene M Kuipers
Journal:  BMC Pediatr       Date:  2022-02-12       Impact factor: 2.125

5.  Surgical exclusion of an idiopathic saccular aneurysm in the left main trunk of the coronary artery.

Authors:  Naoki Tadokoro; Satsuki Fukushima; Yusuke Shimahara; Tetsuya Saito; Naonori Kawamoto; Hideyuki Shimizu; Tomoyuki Fujita
Journal:  Surg Today       Date:  2021-02-19       Impact factor: 2.549

6.  Unexpected Evolution After Multivessel Coronary Artery Bypass Grafting in a Patient With Kawasaki Disease.

Authors:  Samjeris Victor; Kevin C McKillion; Jeffrey A Puette; Patrick McKillion; Matthew B Ellison
Journal:  Cureus       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.